Insider Selling: Acceleron Pharma Inc (NASDAQ:XLRN) EVP Sells 3,622 Shares of Stock

Acceleron Pharma Inc (NASDAQ:XLRN) EVP John D. Quisel sold 3,622 shares of the business’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $44.64, for a total value of $161,686.08. Following the transaction, the executive vice president now directly owns 54,004 shares in the company, valued at approximately $2,410,738.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of XLRN stock opened at $41.49 on Friday. The stock has a market capitalization of $2.19 billion, a PE ratio of -16.02 and a beta of 1.32. Acceleron Pharma Inc has a 1-year low of $32.53 and a 1-year high of $59.59.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Acceleron Pharma had a negative net margin of 849.62% and a negative return on equity of 36.63%. The company had revenue of $3.80 million during the quarter, compared to analyst estimates of $3.21 million. During the same period in the previous year, the company posted ($0.62) EPS. The company’s quarterly revenue was up 2.7% on a year-over-year basis. Sell-side analysts expect that Acceleron Pharma Inc will post -2.15 EPS for the current year.

Several brokerages have recently commented on XLRN. BidaskClub downgraded Acceleron Pharma from a “hold” rating to a “sell” rating in a research note on Friday, April 5th. ValuEngine downgraded Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th. Zacks Investment Research upgraded Acceleron Pharma from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Friday. Barclays downgraded Acceleron Pharma from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $54.00 to $45.00 in a research report on Friday. Finally, Oppenheimer reiterated an “outperform” rating on shares of Acceleron Pharma in a research report on Monday, April 22nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $57.60.

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its position in shares of Acceleron Pharma by 132.1% during the 4th quarter. Bank of New York Mellon Corp now owns 439,644 shares of the biopharmaceutical company’s stock valued at $19,147,000 after purchasing an additional 250,254 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Acceleron Pharma by 33.0% in the third quarter. Vanguard Group Inc. now owns 3,425,363 shares of the biopharmaceutical company’s stock worth $196,034,000 after acquiring an additional 849,608 shares in the last quarter. Emory University bought a new position in Acceleron Pharma in the fourth quarter worth approximately $1,979,000. Putnam Investments LLC boosted its holdings in Acceleron Pharma by 150.9% in the third quarter. Putnam Investments LLC now owns 64,984 shares of the biopharmaceutical company’s stock worth $3,719,000 after acquiring an additional 39,080 shares in the last quarter. Finally, Knott David M boosted its holdings in Acceleron Pharma by 6.1% in the fourth quarter. Knott David M now owns 17,400 shares of the biopharmaceutical company’s stock worth $758,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors own 84.67% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Acceleron Pharma Inc (NASDAQ:XLRN) EVP Sells 3,622 Shares of Stock” was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/04/acceleron-pharma-inc-xlrn-evp-sells-161686-08-in-stock.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Read More: What moving averages are used to define a golden cross?

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.